Recruitment has opened for a new study investigating whether a medicine, (BI 1819479), can improve lung function and quality of life for people with idiopathic pulmonary fibrosis.
- Study locations across NSW, VIC, ACT, TAS and New Zealand
- Participants need to be aged 40 years or older.
- The study compares 3 different doses of BI 1819479 with a placebo.
- Treatment will last between 6 and 12 months.
Participants will be randomised to determine if they receive a low, medium, or high dose – or placebo.
Learn more about the BI 1819479 Study and other open trials on the PACT website Find a Trial page.